Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
39.19
-1.03 (-2.56%)
At close: Sep 25, 2026, 4:00 PM EDT
39.47
+0.28 (0.71%)
After-hours: Sep 25, 2026, 4:41 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $44. The average 1-year stock price forecast is 12.27% higher than the current stock price, while the lowest is $40 (+2.07%) and the highest is $50 (+27.58%).
Price Target: $44 (+12.27%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Initiates $50 | Buy | Initiates | $50 | +27.58% | Sep 23, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +14.83% | Sep 9, 2026 |
| UBS | UBS | Buy Maintains $42 → $48 | Buy | Maintains | $42 → $48 | +22.48% | Sep 4, 2026 |
| Jefferies | Jefferies | Buy Maintains $40 | Buy | Maintains | $40 | +2.07% | Sep 3, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $40 | Buy | Maintains | $40 | +2.07% | Sep 3, 2026 |
Financial Forecast
Revenue This Year
16.66B
from 17.26B
Decreased by -3.45%
Revenue Next Year
17.32B
from 16.66B
Increased by 3.91%
EPS This Year
2.16
EPS Next Year
3.04
from 2.16
Increased by 40.84%
EPS and Forward PE are based on non-GAAP adjusted numbers.